Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: A phase II trial of the Cancer and Leukemia Group B

British Journal of Haematology

Volumn 140, Issue 3, 2008, Pages 313-319

  Smith, Sonali M ^a   Grinblatt, David ^b   Johnson, Jeffrey L ^c   Niedzwiecki, Donna ^c   Rizzieri, David ^c   Bartlett, Nancy L ^d   Cheson, Bruce D ^e  

^a UNIVERSITY OF CHICAGO   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Immunomodulatory drugs; Indolent lymphoma; Phase 2 trial; Thalidomide

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTERY EMBOLISM; ARTICLE; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EMBOLISM; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HEMOPTYSIS; HUMAN; INFECTION; LETHARGY; LUNG DISEASE; LUNG INFILTRATE; LYMPHOCYTOPENIA; MALAISE; MALE; MOOD CHANGE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NONHODGKIN LYMPHOMA; PAIN; PERIPHERAL ISCHEMIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THROMBOEMBOLISM; THROMBOSIS; THROMBUS; VOMITING;

EID: 38949106198     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06937.x     Document Type: Article

References (32)

1. American Society of Clinical Oncology (1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Journal of Clinical Oncology, 12, 2471 2508.
2. Anderson, K.C. (2005) Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Seminars in Hematology, 42, S3 S8.
3. Bel Hadj Jrad, B., Chatti, A., Laatiri, A., Ahmed, S.B., Romdhane, A., Ajimi, S. Chouchane, L. (2007) Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. European Journal of Haematology, 78, 117 122.
4. Bennett, C.L., Schumock, G.T., Desai, A.A., Kwaan, H.C., Raisch, D.W., Newlin, R. Stadler, W. (2002) Thalidomide-associated deep vein thrombosis and pulmonary embolism. The American Journal of Medicine, 113, 603 606.
5. Bertolini, F., Paolucci, M., Peccatori, F., Cinieri, S., Agazzi, A., Ferrucci, P.F., Cocorocchio, E., Goldhirsch, A. Martinelli, G. (1999) Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. British Journal of Haematology, 106, 504 509.
6. Chanan-Khan, A., Miller, K.C., Musial, L., Padmanabhan, S., Lawrence, D., Bernstein, Z., Takeshita, K., Spaner, D., Byrne, C., Chrystal, C. Czuczman, M. (2006) Clinical efficacy of lenalidomide {revlimid®} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): updated results of a phase II clinical trial. Blood, 108, 306a.
7. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
8. D'Amato, R.J., Loughnan, M.S., Flynn, E. Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082 4085.
9. Damaj, G., Lefrere, F., Delarue, R., Varet, B., Furman, R. Hermine, O. (2003) Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia, 17, 1914 1915.
10. Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210 216.
11. Dredge, K., Marriott, J.B., Macdonald, C.D., Man, H.W., Chen, R., Muller, G.W., Stirling, D. Dalgleish, A.G. (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer, 87, 1166 1172.
12. Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P. Anderson, K.C. (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene, 20, 4519 4527.
13. Ikhlaque, N., Seshadri, V., Kathula, S. Baumann, M.A. (2006) Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. American Journal of Hematology, 81, 420 422.
14. Kaplan, E. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 47, 583 621.
15. Kaufmann, H., Raderer, M., Wohrer, S., Puspok, A., Bankier, A., Zielinski, C., Chott, A. Drach, J. (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood, 104, 2269 2271.
16. Krown, S.E., Niedzwiecki, D., Hwu, W.J., Hodgson, L., Houghton, A.N. Haluska, F.G. (2006) Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer, 107, 1883 1890.
17. Miller, K.C., Padmanabhan, S., Dimicelli, L., Depaolo, D., Landrigan, B., Yu, J., Doran, V., Marshal, P. Chanan-Khan, A. (2006) Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leukemia & Lymphoma, 47, 2339 2343.
18. Neben, K., Mytilineos, J., Moehler, T.M., Preiss, A., Kraemer, A., Ho, A.D., Opelz, G. Goldschmidt, H. (2002) Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood, 100, 2263 2265.
19. Palumbo, A., Rus, C., Zeldis, J.B., Rodeghiero, F. Boccadoro, M. (2006) Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. Journal of Thrombosis and Haemostasis, 4, 1842 1845.
20. Pro, B., Younes, A., Albitar, M., Dang, N.H., Samaniego, F., Romaguera, J., McLaughlin, P., Hagemeister, F.B., Rodriguez, M.A., Clemons, M. Cabanillas, F. (2004) Thalidomide for patients with recurrent lymphoma. Cancer, 100, 1186 1189.
21. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E. Anderson, K.C. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, 3458 3464.
22. Rothman, N., Skibola, C.F., Wang, S.S., Morgan, G., Lan, Q., Smith, M.T., Spinelli, J.J., Willett, E., De Sanjose, S., Cocco, P., Berndt, S.I., Brennan, P., Brooks-Wilson, A., Wacholder, S., Becker, N., Hartge, P., Zheng, T., Roman, E., Holly, E.A., Boffetta, P., Armstrong, B., Cozen, W., Linet, M., Bosch, F.X., Ennas, M.G., Holford, T.R., Gallagher, R.P., Rollinson, S., Bracci, P.M., Cerhan, J.R., Whitby, D., Moore, P.S., Leaderer, B., Lai, A., Spink, C., Davis, S., Bosch, R., Scarpa, A., Zhang, Y., Severson, R.K., Yeager, M., Chanock, S. Nieters, A. (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the Interlymph Consortium. The Lancet Oncology, 7, 27 38.
23. Ruan, J., Hyjek, E., Kermani, P., Christos, P.J., Hooper, A.T., Coleman, M., Hempstead, B., Leonard, J.P., Chadburn, A. Rafii, S. (2006) Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clinical Cancer Research, 12, 5622 5631.
24. Salven, P., Orpana, A., Teerenhovi, L. Joensuu, H. (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood, 96, 3712 3718.
25. Seidemann, K., Zimmermann, M., Book, M., Meyer, U., Burkhardt, B., Welte, K., Reiter, A. Stanulla, M. (2005) Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Munster Trial NHL-BFM 95. Journal of Clinical Oncology, 23, 8414 8421.
26. Teo, S.K., Resztak, K.E., Scheffler, M.A., Kook, K.A., Zeldis, J.B., Stirling, D.I. Thomas, S.D. (2002) Thalidomide in the treatment of leprosy. Microbes and Infection, 4, 1193 1202.
27. Teo, S.K., Stirling, D.I. Zeldis, J.B. (2005) Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discovery Today, 10, 107 114.
28. Wiernik, P.H., Lossos, I.S., Tuscano, J., Justice, G., Vose, J., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J. Habermann, T. (2006) Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood, 108, 531a.
29. Wilson, E.A., Jobanputra, S., Jackson, R., Parker, A.N. McQuaker, I.G. (2002) Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. British Journal of Haematology, 119, 128 130.
30. Witzig, T.E., Vose, J., Kaplan, H.P., Wolf, J.L., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J. Wiernik, P.H. (2006) Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood, 108, 2482a.
31. Zapata, J.M., Krajewska, M., Krajewski, S., Kitada, S., Welsh, K., Monks, A., McCloskey, N., Gordon, J., Kipps, T.J., Gascoyne, R.D., Shabaik, A. Reed, J.C. (2000) TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. The Journal of Immunology, 165, 5084 5096.
32. Zapata, J.M., Krajewska, M., Morse, III., H.C., Choi, Y. Reed, J.C. (2004) TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 101, 16600 16605.